Objective: To review novel therapeutics in development for treatment of eosinophilic gastrointestinal disorders (EGIDs). Data Sources: Clinical trial data (clinicaltrials.gov) and literature search on PubMed. Study Selections: Studies on treatment and clinical trials in EGIDs were included in this review. Results: During the past decade, significant progress has been made in understanding disease mechanisms in EGIDs. As a result, a variety of novel therapeutics have been developed for treatment of these disorders. Several monoclonal antibodies against targets, including interleukin (IL) 4, IL-5, IL-13, integrins, and siglec-8, have shown promise in early trials. Novel formulations of corticosteroids are also in development. Conclusion: The field of EGID research has advanced rapidly, and disease-modifying therapeutics are closer to clinical application.
ASJC Scopus subject areas
- Immunology and Allergy
- Pulmonary and Respiratory Medicine